Larimar to Present at 44th J.P. Morgan Healthcare Conference on January 14, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Globenewswire
- Investor Meeting Participation: Larimar Therapeutics will participate in 1x1 investor meetings at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in treatments for complex rare diseases, which is expected to attract potential investor interest.
- Product Development Progress: The company's lead compound, nomlabofusp, is under development as a treatment for Friedreich's ataxia, and this innovation could open new market opportunities, enhancing its competitive position in the biotechnology sector.
- Webcast Arrangement: The presentation is scheduled from 9:00 to 9:40 AM PST, and investors can join via the provided webcast link, with a replay available for 30 days on the company’s website, thereby improving engagement with investors.
- Future Development Strategy: Larimar plans to leverage its intracellular delivery platform to design additional fusion proteins targeting more rare diseases, demonstrating the company's long-term growth potential and ongoing commitment to innovation in the biotechnology field.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LRMR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LRMR
Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 21.50 USD with a low forecast of 21.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.680
Low
21.00
Averages
21.50
High
22.00
Current: 3.680
Low
21.00
Averages
21.50
High
22.00
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Larimar to Present at 44th J.P. Morgan Healthcare Conference on January 14, 2026
- Investor Meeting Participation: Larimar Therapeutics will participate in 1x1 investor meetings at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in treatments for complex rare diseases, which is expected to attract potential investor interest.
- Product Development Progress: The company's lead compound, nomlabofusp, is under development as a treatment for Friedreich's ataxia, and this innovation could open new market opportunities, enhancing its competitive position in the biotechnology sector.
- Webcast Arrangement: The presentation is scheduled from 9:00 to 9:40 AM PST, and investors can join via the provided webcast link, with a replay available for 30 days on the company’s website, thereby improving engagement with investors.
- Future Development Strategy: Larimar plans to leverage its intracellular delivery platform to design additional fusion proteins targeting more rare diseases, demonstrating the company's long-term growth potential and ongoing commitment to innovation in the biotechnology field.
Continue Reading
Three Health Care Stocks Poised for Significant Gains This December
Oversold Stocks Opportunity: The health care sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.
Larimar Therapeutics Inc: The company reported a wider-than-expected quarterly loss, with its stock falling 20% over the past month and an RSI of 29.9, closing at $3.12.
Perrigo Company PLC: Perrigo's mixed financial results led to a 34% stock decline in the past month, with an RSI of 29.9, closing at $13.61, despite gaining market share in several categories.
ORIC Pharmaceuticals Inc: After a recent coverage initiation with an Outperform rating, ORIC's stock fell 16% over the past month, with an RSI of 29.6, closing at $10.65.
Continue Reading